SLC5A2 and Myocardial fibrosis: Myocardial fibrosis might be predictive of adverse outcomes among subjects with recent episodes of acute HF [49]; however, amelioration of myocardial fibrosis by SGLT-2 inhibitors might not provide any significant benefit in the acute setting of HF.